| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
- Reuters
Texas judge rejects bid to block Kenvue's $398 million dividend and declines to restrict Tylenol marketing as the company f...
Barclays analyst Lauren Lieberman maintains Kenvue (NYSE:KVUE) with a Equal-Weight and raises the price target from $17 to $18.
https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-fights-stop-manufacturer-tylenol-fraudulently-pa...
https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-fights-stop-manufacturer-tylenol-fraudulently-pa...
The $48.7 billion Kimberly-Clark–Kenvue deal could reshape major consumer staples ETFs like XLP, VDC, and IYK.
Although Kimberly-Clark suffered a huge blow after announcing its Kenvue buyout, KMB stock is flashing a quantitative contraria...
Wall Street opened the week on a mixed note on Monday.